Skip to main content
Equibles

CL · Cresco Labs Inc. · Documents

Use CL with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research CL.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
0.7900 CAD +0.0000 (+0.00%) At close · Nov 6 Intraday price with Plus
Rebalance outlook locked

The company's reports, filings, earnings calls and investor events, most recent first. Search these from Claude or ChatGPT →

Annual report FY2025 Revenue $655.85M down 9.5% 40-F filed Mar 6, 2026 Earnings call New Q3 2026 earnings call Held Nov 6, 2026
2026
Nov 6
Earnings call
Revenue rose 5% as free cash flow reached $21 million

Cresco Labs reported third-quarter 2026 revenue of $173 million, up 5% year-over-year, adjusted EBITDA of $35 million and free cash flow of $21 million after acquiring nine Pennsylvania dispensaries.

3 source passages
Good morning, everyone, and thank you for joining Cresco Labs' third quarter 2026 earnings call. We generated $173 million in revenue, up 5% year-over-year. We produced $81 million in adjusted gross profit. We produced $35 million in adjusted EBITDA, resulting in a 20% margin. And we generated $26 million in operating cash flow, up from $15 million in Q2, and $21 million in free cash flow. On September 2nd, we closed the acquisition of the nine Pennsylvania dispensaries, a state where our scaled position gives us operating leverage. Open the document at this passage
Nov 6
Current report 6-K
Revenue rose as net loss narrowed

Cresco Labs reported revenue of 172,782 for the three months ended September 30, 2026 versus 164,913 in 2025, while net loss narrowed to (14,533) from (21,968), in thousands of United States Dollars.

Read from the first part of this long document
4 source passages
Cresco Labs Inc. Unaudited Condensed Interim Consolidated Statements of Operations and Comprehensive Loss For the Three and Nine Months Ended September 30, 2026 and 2025 (In thousands of United States Dollars, except share and per share amounts) Revenues, net | 172,782 | 164,913 | 497,448 | 494,294 Net loss | (14,533) | (21,968) | (16,178) | (51,095) Open the document at this passage
Nov 3
Current report 6-K
Shareholders approve restructuring for potential U.S. exchange listing

Cresco Labs shareholders approved three special resolutions on October 30, 2026 covering a new parent company, a potential British Columbia-to-Delaware redomicile, and an extended listing sunset date; seven directors were elected, and every matter received at least 94% approval.

8 source passages
Shareholders approved measures that streamline capital structure and governance to position the Company for a potential senior U.S. exchange listing Cresco Labs Inc. (CSE: CL) (OTCQX: CRLBF) (FSE: 6CQ) (“Cresco Labs” or the “Company”), today announced the results of its annual general and special meeting of shareholders (the “Meeting”) held on October 30, 2026. At the Meeting, shareholders approved three special resolutions relating to: (1)creation of a new parent company (“TopCo”) and exchange of Cresco Labs securities and participating Cresco Labs LLC membership interests for TopCo securities, (2)a potential, subsequent redomicile of TopCo from British Columbia to Delaware, and (3)an extension of the listing sunset date applicable to the Company's multiple voting shares from the first to the third anniversary of a U.S. listing. Shareholders also voted to approve other annual items of business, including electing the following seven directors: Each of the foregoing matters was approved by at least 94% of the shares voted at the Meeting. Open the document at this passage
Oct 13
Current report 6-K
Current report

Cresco Labs Inc.’s October 30, 2026 shareholder meeting has approximately 73% Multiple Voting Shares, 26% Subordinate Voting Shares, 1% Proportionate Voting Shares, and 0.0001% Special Subordinate Voting Shares. Affected securities vote separately on minority approval; existing proxies remain valid.

Sep 30
Current report 6-K
Current report

Cresco Labs Inc. shareholders will vote on October 30, 2026 on creating TopCo, exchanging Cresco securities for TopCo shares through a reverse split, redomiciling to Delaware, extending the Multiple Voting Shares’ listing sunset; the board recommends all resolutions.

Read from the first part of this long document
Showing 1–50 of 598 documents